ArticleBlood2021
Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Mitochondria as the Hub of Apoptosis: A Comprehensive Insight From Mitochondria to Interactions With Other Organelles.MedComm · 2026Review
- Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.Leukemia · 2026Article
- Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know.Pharmacy (Basel, Switzerland) · 2025Review
- Review
- Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia.HemaSphere · 2025Article
- Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies.Blood cancer discovery · 2025Review
- Inhibition of the CXCR4/PLC Signaling Increases Dexamethasone-Induced Sensitivity by Activating the Mitochondrial Apoptotic Pathway in B-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2025Article
- Article
- Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case ReportTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience.HemaSphere · 2024Article
- Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.Clinical pharmacokinetics · 2024Article
- Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.Haematologica · 2024Review
- Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.Annals of hematology · 2023Article
- CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.Blood advances · 2023Article
- Case Report: RareGenes · 2023Article
- Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.Frontiers in immunology · 2023Review
- Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?Clinical hematology international · 2022Review
- Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia.HemaSphere · 2022Article
- Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart.Cancers · 2022Article
- Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?Hematology. American Society of Hematology. Education Program · 2021Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
Adult patients with relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a dismal prognosis. To improve pharmacotherapy, we analyzed induction of apoptosis by venetoclax and inotuzumab ozogamicin in terms of cytotoxicity and mode of action. Flow cytometry-based analyses of mitochondrial outer membrane permeabilization (MOMP) and ataxia telangiectasia mutated activation demonstrate rapid induction of MOMP by venetoclax and DNA damage signaling by inotuzumab ozogamicin, respectively. In primary ALL samples and patient-derived xenograft (PDX) models, venetoclax and inotuzumab ozogamicin cooperated and synergized in combination with dexamethasone in vitro in all tested samples of ALL. In murine PDX models, inotuzumab ozogamicin, but not venetoclax, induced complete remission in a dose-dependent manner but constantly failed to achieve relapse-free survival. In contrast, combination therapy with venetoclax, dexamethasone, and inotuzumab ozogamicin induced long-term leukemia-free survival and treatment-free survival in all 3 ALL-PDX models tested. These data demonstrate synergistic and highly efficient pharmacotherapy in preclinical models that qualify for evaluation in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.